高级检索
当前位置: 首页 > 详情页

Vitexin protects against ethanol-induced liver injury through Sirt1/p53 signaling pathway

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Mathematical Engineering Academy of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China [2]School of pharmaceutical sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China [3]Department of Hepatobiliary Surgery, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China [4]The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
出处:
ISSN:

关键词: Vitexin Apoptosis Alcoholic liver disease Liver injury Sirt1/p53 pathway

摘要:
In the present study, we aimed to investigate the therapeutic effect of Vitexin on inhibiting ethanol-induced liver damage and explore the underling mechanism. In vitro, the injury was induced in LO2 cell by 100 mM ethanol. Cell viability, AST, oxidative stress, inflammation, apoptosis rate, and related gene and protein expressions were assessed. Alcoholic liver injury model was made by intragastric infusion of alcohol for 4 weeks on male KM mice. Liver index, AST, ALT, TC, TG, TP, TBIL in serum and liver pathology were evaluated. Meanwhile, the level of SOD, MDA and TNF-alpha also were detected by Kits. Quantitative RT-PCR and Western blotting analysis the Sirt1/p53 pathway related gene and protein expressions. In vitro, Vitexin restored cytoactive and inhibited the releasing of AST induced by ethanol in LO2 cell. Vitexin treatment significantly suppressed the elevation of aminotransferase, blood lipid, UA in mice. Vitexin ameliorated liver pathological changes induced by ethanol. Vitexin supplement restored the decrease of Sirt1/Bcl-2 expression, restrained the elevation of caspase3, cleaved caspse-3, p53 and ac-p53 expression in vivo and in vitro. Vitexin has a protective effect against ethanol-induced liver damage, and the underlying mechanism is probably through Sirt1/p53 mediated mitochondrial apoptotic pathway.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 3 区 医学
小类 | 3 区 药学
最新[2025]版:
大类 | 3 区 医学
小类 | 2 区 药学
JCR分区:
出版当年[2018]版:
Q2 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Mathematical Engineering Academy of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China [2]School of pharmaceutical sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
共同第一作者:
通讯作者:
通讯机构: [2]School of pharmaceutical sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China [3]Department of Hepatobiliary Surgery, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China [*1]School of pharmaceutical sciences, Guangzhou University of Chinese Medicine, University Town, Guangzhou, Guangdong, 510006, China [*2]Department of Hepatobiliary Surgery, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, 510630, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号